Biotech that bought GSK's 'bubble boy' drug to build stem cell manufacturing facility in U.S.

8th October 2018 Uncategorised 0

U.K.-based Orchard Therapeutics intends to spend some of the proceeds of an IPO to build a cell production facility in the San Francisco area and use the rest to take three gene therapies through the clinic and onto the market.

More: Biotech that bought GSK's 'bubble boy' drug to build stem cell manufacturing facility in U.S.
Source: fierce